Gotowa bibliografia na temat „Minimal pharmacophores”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Minimal pharmacophores”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Minimal pharmacophores"
Mortier, Jérémie, Pratik Dhakal i Andrea Volkamer. "Truly Target-Focused Pharmacophore Modeling: A Novel Tool for Mapping Intermolecular Surfaces". Molecules 23, nr 8 (6.08.2018): 1959. http://dx.doi.org/10.3390/molecules23081959.
Pełny tekst źródłaPetrikaite, Vilma, Eduardas Tarasevišius i Alvydas Pavilonis. "New ethacridine derivatives as the potential antifungal and antibacterial preparations". Medicina 43, nr 8 (11.08.2007): 657. http://dx.doi.org/10.3390/medicina43080084.
Pełny tekst źródłaSpasov, Alexander, Irina Ovchinnikova, Olga Fedorova, Yulia Titova, Denis Babkov, Vadim Kosolapov, Alexander Borisov i in. "Amino Derivatives of Diaryl Pyrimidines and Azolopyrimidines as Protective Agents against LPS-Induced Acute Lung Injury". Molecules 28, nr 2 (11.01.2023): 741. http://dx.doi.org/10.3390/molecules28020741.
Pełny tekst źródłaMishra, Pranjali, Muskan Srivastav, Yashveer Gautam, Monal Singh, Neeraj Verma, Deepak S. Kapkoti, Shailendra P. Singh, Anil K. Singh i Devendra P. Rao. "A REVIEW IN CURCUMINOIDS: CHEMISTRY, ANTICANCER ACTIVITY AND FUTURE PROSPECTS". INDIAN DRUGS 61, nr 05 (28.05.2024): 7–23. http://dx.doi.org/10.53879/id.61.05.14041.
Pełny tekst źródłaMaatuf, Yossi, Matan Geron i Avi Priel. "The Role of Toxins in the Pursuit for Novel Analgesics". Toxins 11, nr 2 (23.02.2019): 131. http://dx.doi.org/10.3390/toxins11020131.
Pełny tekst źródłaWermelinger, Guilherme Freimann, Lucas Rubini, Anna Carolina Carvalho da Fonseca, Gabriel Ouverney, Rafael P. R. F. de Oliveira, Acácio S. de Souza, Luana S. M. Forezi, Gabriel Limaverde-Sousa, Sergio Pinheiro i Bruno Kaufmann Robbs. "A Novel MDM2-Binding Chalcone Induces Apoptosis of Oral Squamous Cell Carcinoma". Biomedicines 11, nr 6 (14.06.2023): 1711. http://dx.doi.org/10.3390/biomedicines11061711.
Pełny tekst źródłaBourne, Yves, Gerlind Sulzenbacher, Laurent Chabaud, Rómulo Aráoz, Zoran Radić, Sandrine Conrod, Palmer Taylor, Catherine Guillou, Jordi Molgó i Pascale Marchot. "The Cyclic Imine Core Common to the Marine Macrocyclic Toxins Is Sufficient to Dictate Nicotinic Acetylcholine Receptor Antagonism". Marine Drugs 22, nr 4 (27.03.2024): 149. http://dx.doi.org/10.3390/md22040149.
Pełny tekst źródłaCaldas Lopes, Eloisi, Shieh Jae-Hung, Srikanth Ambati, Su Tsann-Long, Fabian Correa, Elizabeth Peguero i Malcolm A. S. Moore. "Novel Alkylating Agent, Ureidomustine Exhibit Pre-Clinical Efficacy in B-Cell Lymphoma with Minimal Dose-Limiting Myelotoxicity". Blood 126, nr 23 (3.12.2015): 1556. http://dx.doi.org/10.1182/blood.v126.23.1556.1556.
Pełny tekst źródłaVawhal, Pallavi Kishor, Shailaja B. Jadhav, Sumit Kaushik, Kahnu Charan Panigrahi, Chandan Nayak, Humaira Urmee, Sharuk L. Khan i in. "Coumarin-Based Sulfonamide Derivatives as Potential DPP-IV Inhibitors: Pre-ADME Analysis, Toxicity Profile, Computational Analysis, and In Vitro Enzyme Assay". Molecules 28, nr 3 (19.01.2023): 1004. http://dx.doi.org/10.3390/molecules28031004.
Pełny tekst źródłaRobertson, Gregory T., Eric J. Bonventre, Timothy B. Doyle, Qun Du, Leonard Duncan, Timothy W. Morris, Eric D. Roche, Dalai Yan i A. Simon Lynch. "In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Microbiology Profiling Studies with Staphylococci and Streptococci". Antimicrobial Agents and Chemotherapy 52, nr 7 (lipiec 2008): 2324–34. http://dx.doi.org/10.1128/aac.01651-07.
Pełny tekst źródłaRozprawy doktorskie na temat "Minimal pharmacophores"
Su, Li. "Generation of analogues of the anti-tumor polyketide stambomycins by genetic engineering and allied approaches". Electronic Thesis or Diss., Université de Lorraine, 2021. http://www.theses.fr/2021LORR0081.
Pełny tekst źródłaThe polyketide secondary metabolites of bacteria are a rich source of bioactive agents, with notable applications in anti-infective and anti-cancer therapy. However, their structures often need to be optimized in order to tailor their therapeutic and biophysical properties. The 51-membered macrolide stambomycins, among the largest of known polyketides, were recently discovered by genome mining in Streptomyces ambofaciens ATCC23877, and notably exhibit promising anti-cancer activity. The family encompasses six members which differ from each other in the alkyl functionality at C-26, due to the alternative choice of extender units by an exceptional acyl transferase domain (AT12) of the modular polyketide synthase (PKS) responsible for synthesizing the stambomycin core. Given their enormous size of the stambomycins and the intrinsic promiscuity of AT12, there is substantial interest in accessing ring-contracted and C-26 substituted derivatives of this compounds which might retain the bioactivity of the parental structures, or exhibit improved or even new properties. In this work, we have leveraged our current understanding of modular PKS systems to internally contract the stambomycin assembly line, leading to the successful generation, albeit at low yield, of target smaller derivatives (37-membered ‘mini-stambomycins’). By careful analysis, we could identify multiple factors contributing to the low titers, information which should inform future engineering strategies. Furthermore, using a mutasynthesis strategy, we were able to exploit the broad specificity of the AT12 domain to create 6 novel C-26 substituted stambomycin analogues. Finally, we unexpectedly identified three series of novel desferrioxamine siderophores produced by S. ambofaciens. As a number of key metabolites generated in this work have potential interest for therapeutic applications, they will be targeted for purification, structural characterization and biological evaluation
Części książek na temat "Minimal pharmacophores"
Rijkers, Dirk T. S., Jack A. J. den Hartog i Rob M. J. Liskamp. "Structure-Activity Studies on the Corticotropin Releasing Factor Antagonist Astressin, Minimal Sequence Necessary for Antagonistic Activity: Implications for a New Pharmacophoric Model". W Peptides: The Wave of the Future, 727–28. Dordrecht: Springer Netherlands, 2001. http://dx.doi.org/10.1007/978-94-010-0464-0_339.
Pełny tekst źródła